Loading patent…
AssigneeAllergan, Inc.
InventorsDavid F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
Estimating the term…
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, either or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
A method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula III. ##STR11## wherein hatched lines indicate .alpha. configuration and solid triangles indicate .beta. configuration, and the dashed bonds represent a single or double bond which can be in the cis or trans configuration;
A pharmaceutical composition for treating ocular hypertension which comprises a therapeutically-effective amount of a compound of formula III. ##STR14## wherein hatched lines indicate .alpha. configuration and solid lines indicate .beta. configuration, and the dashed bonds represent a single or double bond which can be in the cis or trans configuration;
Dependencies are inferred from the claim text.